Norman David Eansor Net Worth

The estimated Net Worth of Norman David Eansor is at least $3.64 Million dollars as of 12 November 2021. Mr Eansor owns over 27,958 units of Bio-Techne Corp stock worth over $155,578 and over the last 21 years he sold TECH stock worth over $1,884,382. In addition, he makes $1,598,732 as Pres of Protein Sciences Segment at Bio-Techne Corp.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr Eansor TECH stock SEC Form 4 insiders trading

Mr has made over 14 trades of the Bio-Techne Corp stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 27,958 units of TECH stock worth $3,496,148 on 12 November 2021.

The largest trade he's ever made was exercising 32,933 units of Bio-Techne Corp stock on 5 February 2021 worth over $3,510,328. On average, Mr trades about 3,534 units every 65 days since 2003. As of 12 November 2021 he still owns at least 2,117 units of Bio-Techne Corp stock.

You can see the complete history of Mr Eansor stock trades at the bottom of the page.

Mr. Norman David Eansor biography

Norman David Eansor is the Pres of Protein Sciences Segment at Bio-Techne Corp.

What is the salary of Mr Eansor?

As the Pres of Protein Sciences Segment of Bio-Techne Corp, the total compensation of Mr Eansor at Bio-Techne Corp is $1,598,732. There are 7 executives at Bio-Techne Corp getting paid more, with Charles Kummeth having the highest compensation of $11,483,800.

How old is Mr Eansor?

Mr Eansor is 59, he's been the Pres of Protein Sciences Segment of Bio-Techne Corp since . There are 8 older and 9 younger executives at Bio-Techne Corp. The oldest executive at Bio-Techne Corp is Roeland Nusse, 70, who is the Independent Director.

What's Mr Eansor's mailing address?

Norman's mailing address filed with the SEC is 8100 Southpark Way, Littleton, CO 80120, USA.

Insiders trading at Bio-Techne Corp

Over the last 22 years, insiders at Bio-Techne Corp have traded over $37,160,097 worth of Bio-Techne Corp stock and bought 4,361 units worth $454,370 . The most active insiders traders include Charles R. Kummeth, Rupert Vessey, and John L Higgins. On average, Bio-Techne Corp executives and independent directors trade stock every 23 days with the average trade being worth of $964,850. The most recent stock trade was executed by Kim Kelderman on 29 August 2024, trading 1,492 units of TECH stock currently worth $99,919.

What does Bio-Techne Corp do?

bio-techne (formerly techne corp.), nasdaq: tech, is a global life sciences company providing innovative bioactive tools and resources for the research and clinical diagnostic communities. bio-techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. they aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. with over 275,000 products in its portfolio, bio-techne generated approximately $358 million in net sales in fy 2014 and has over 1,000 employees worldwide.

Complete history of Mr Eansor stock trades at Bio-Techne Corp and Marker Therapeutics

Bio-Techne Corp executives and stock owners

Bio-Techne Corp executives and other stock owners filed with the SEC include:

• Charles Kummeth,
  President, Chief Executive Officer, Director
• Charles R. Kummeth,
  CEO, Pres & Director
• James Hippel,
  Chief Financial Officer, Executive Vice President - Finance
• David Eansor,
  President - Protein Sciences
• Kim Kelderman,
  President - Diagnostics and Genomics
• Brenda Furlow,
  Senior Vice President, General Counsel, Corporate Secretary
• James T. Hippel,
  Exec. VP of Fin. & CFO
• Norman David Eansor,
  Pres of Protein Sciences Segment
• Kim Kelderman,
  Pres of Diagnostics & Genomics
• Brenda S. Furlow J.D.,
  Exec. VP, Gen. Counsel, Sec. & Chief Compliance Officer
• Robert Baumgartner,
  Independent Chairman of the Board
• Rupert Vessey,
  Independent Director
• John Higgins,
  Independent Director
• Randolph Steer,
  Independent Director
• Roeland Nusse,
  Independent Director
• Alpna Seth,
  Independent Director
• Joseph Keegan,
  Independent Director
• David Clair,
  IR Contact Officer
• Julie Bushman,
  Independent Director
• Kevin Smyth,
  Sr. VP & Chief Digital Officer
• Luca Cicchetti,
  Managing Director
• Brenda Everson,
  Sr. VP of HR
• Kevin S. Gould,
  Sr. VP of Diagnostics Reagents Division
• Struan Robertson,
  VP of HR
• Robert M. Gavin,
  VP of Corp. Devel.
• Gerry Andros,
  VP of Sales and Marketing
• Karen A Holbrook,
  Director
• Roger C Lucas,
  
• Charles A Dinarello,
  
• J. Fernando Bazan,
  Chief Technical Officer
• Robert M. Gavin,
  Sen. VP Protein Platforms
• Kevin S Gould,
  SVP Clinical Controls
• Kevin J Reagan,
  Senior VP Biotech
• Gregory J Melsen,
  VP Finance and CFO
• Thomas E Oland,
  President
• Howard V Oconnell,
  Director
• Marcel Veronneau,
  Vice Pres-Hematology Oper.
• James A Weatherbee,
  Chief Scientific Officers
• Monica Tsang,
  Vice President of Research
• Christopher S Henney,
  Director
• G A Herbert,
  Director
• Harold J Wiens,
  
• William Geist,
  PRESIDENT, PROTEIN SCIENCES
• Shane Bohnen,
  SVP - General Counsel
• Matthew Mc Manus,
  President - DGS
• Judith V Klimovsky,
  Director